Literature DB >> 2275006

Human scalp hair as evidence of individual dosage history of haloperidol: longer-term follow-up study.

T Uematsu1, R Sato.   

Abstract

The patients reported in our previous paper were followed further, by analyzing hair samples collected monthly for 4 or 5 months, while growing hair continues to reflect the individual dosage history of haloperidol. In patients in whom the drug had been discontinued, the portion of hair that reflected the change of dose continued to move upward. In hair of patients in whom the dosage was decreased by one-half, the portion of change was also shown to move upward. These results indicate the potential usefulness of hair for assessing the individual past dosage history of haloperidol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275006     DOI: 10.1097/00007691-199011000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

Review 1.  Therapeutic drug monitoring in hair samples. Principles and practice.

Authors:  T Uematsu
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

2.  Chlorpromazine in human scalp hair as an index of dosage history: comparison with simultaneously measured haloperidol.

Authors:  H Sato; T Uematsu; K Yamada; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol.

Authors:  M Nakano; T Uematsu; H Sato; K Kosuge; M Nishimoto; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  The measurement of a new antimicrobial quinolone in hair as an index of drug exposure.

Authors:  T Uematsu; M Nakano; H Akiyama; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

5.  Analysis of a new fluoroquinolone derivative (Q-35) in human scalp hair as an index of drug exposure and as a time marker in hair.

Authors:  T Uematsu; Y Ohsawa; A Mizuno; M Nakashima
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.